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Autism spectrum disorder (ASD) involves a range of early-onset neurodevelopmental conditions featured by impaired social interactions and communications, together with repetitive stereotypic behaviors (DSM5). In the last decades, there has been considerable increase in the prevalence of this pervasive developmental disorder, which may be due to the interplay between worsened environmental factors (prenatal, pollution, etc.) and undoubted heritable factors.
ASD does not meet the criteria of known models of inheritance. For most patients, the polygenic pattern of inheritance with many interacting genes is the most expected model. However, the etiology of ASD is not fully understood. So far, it has been hard to understand how various genetic susceptibilities translate to a clinical phenotype with many genomic loci resulting in heterogeneous functions. 1 Because of the increasing social burden and the variability in clinical presentation, the search for biomarkers is a leading line in autism research expecting to enable early diagnosis and more successful therapeutic interventions. Until now, studies have centered more on genetic factors, but only a few studies have investigated the role of miRNA as epigenetic factors involved in ASD. [2] [3] [4] Epigenetic factors regulate heritable modifi cations in gene function or activity without changes of the DNA sequence.
МicroRNAs have recently became leading epigenetic regulators of various cellular processes. They are small, non-coding, single-stranded RNA molecules of around 22 nucleotides (nt) in length. MicroRNAs are themselves active molecules that affect gene function, and thus their expression may be associated with altered cell physiology. There is increasing evidence that has linked miRNAs with regulation of many biological pathways and processes like cell development, proliferation, differentiation, and apoptosis. 5 As a group of important endogenous molecules they modulate gene expression by recognizing complementary sequences in target messenger RNAs (mRNAs), implicated in normal cell function. 6 The dysregulation of miRNA expression can profoundly alter the gene expression pattern by means of post-transcriptional gene silencing including different mechanisms. 7 MiRNAs, previously known to be expressed only in cells and tissues, have also been detected in extracellular body fl uids such as serum, plasma, saliva, urine, breast milk, seminal plasma, tears, amniotic fl uid, colostrum, bronchial lavage, cerebrospinal fl uid, peritoneal fl uid, and pleural fl uid. 8, 9 Although the miRNAs transcriptomic connection between serum and brain is not well known, numerous lines of evidence suggest that examination in tissues that are not primarily involved in the disease process may reveal disease signatures. Several investigators have demonstrated differential expression of genes in peripheral white blood cells in disorders of the central nervous system. [10] [11] [12] [13] The fi ndings from that research may suggest that altered miRNA expression profi les target genes closely involved in neurological functions and disorders and, in turn, may lead to the pathophysiological conditions associated with autism. Altered expression of cellular and circulating miRNAs have been observed in autistic individuals compared to healthy controls. MicroRNAs are now being considered as potential targets for the development of novel therapeutic strategies for autism.
Serum miRNAs which may be collected from circulating blood cells are known particularly to be very stable, reproducible and resistant to the actions of RNase, 14 suggesting effi cacy as noninvasive biomarkers for ASD.
AIM
The aim of this study was to test whether circulating miRNAs display differential expression profi le in serum of ASD patients in comparison with typically developing children.
PATIENTS AND METHODS
ETHICS STATEMENT This study's design and the Informed Consent Form (ICF) were approved by the Ethics Committee of Plovdiv Medical University. The University Institutional Review Board approved the use of the samples for this study. Written ICFs were obtained from the parents of the probands and the children of the control group after the objectives of the study had been explained and confi dentiality ensured. PATIENTS A total of 30 subjects (24 male and 6 female) with ASD aged 3 to 11 years (mean age of the sample, 6.86 years), and 30 healthy children age-and sexmatched to the patient's group were recruited between March 2013 and February 2014. All probands were randomly selected from the Pediatric Department of the Plovdiv Medical University Hospital Database. Parents of the participants were interviewed by experienced psychiatrists and the diagnose of ASD was made by clinical examination, ADI-R 15 , CARS and GARS 16 , adhering to the DSM V criteria. The control group was assigned from several family practices in the Plovdiv region aiming to be matched by age and sex to the probands' group. All children in the control group were examined for absence of autistic features by clinical examination and CARS. All participants were Bulgarians. None of the participants had received any medications before blood sampling. BLOOD COLLECTION, SERUM PROCESSING AND RNA EX-TRACTION Blood samples (4 ml) were drawn, collected in EDTA containing tubes and stored at 4°C before centrifugation. The samples were separated into serum and blood cells by centrifuging at 1600 g for 10 min at 4°C. A volume of 500 μl serum was recentrifuged at 16 000 g for 10 min at 4°C to remove any residual blood cells. The clear supernatant was collected into RNase/DNase-free microfuge tubes in 300 μl aliquots and stored at -80°C until use. Total serum RNA including miRNAs was extracted from the samples, where a 5 μl synthetic spike-in control, Caenorhabditis elegans miR-39 (100nM), were previously added for internal normalization. Total serum RNA extraction were performed by using the PAXgene blood miRNA kit (PreAnalytiX), according to the "Manual Purifi cation of Total RNA, Including miRNA protocol" recommended by the manufacturer with some modifi cations including starting the purifi cation at step 4 and elution in 30 μl of BR5 buffer.
STEM-LOOP REAL-TIME PCR QUANTIFICATION OF SERUM

MICRORNAS
Five microliters of each RNA sample was used for miRNA specifi c cDNA synthesis using Maxima First Strand cDNA Synthesis Kit (Thermo Scientifi c) and miRNA-specifi c stem-loop primers. Reverse transcription reactions contained 8 μl of total RNA samples, 4 μl miRNA specifi c cDNA synthesis SL primer mix (100 μm each), 4 μl Maxima Enzyme Mix, 4 μl 5X Reaction Mix and nuclease free water to a fi nal volume of 20 μl. MicroRNA-specifi c stem-loop (SL) and forward primers (For) used in this study are summarized in Table 1 .
Five microliters of each miRNA specifi c cDNA were subjected to pre-amplifi cation prior to the realtime PCR step with peqGOLD Taq DNA Polymerase to potentially enhance sensitivity of the assay. qRT-PCR was performed using Maxima SYBR Green qPCR Master Mix (Тhermo Fisher Scientifi c) with ABI 7500 system (Applied Biosystems). Each sample was normalized using spiked-in synthetic C. elegans miRNAs as controls. Experiments were performed in duplicate. The expression levels of miRNAs for qRT-PCR were normalized to cel-miR-39, and relative quantifi cation (RQ) was calculated utilizing the 2 −ΔΔCt method.
STEM-LOOP QRT-PCR POOLED EXPRESSION ANALYSIS OF SERUM MICRORNAS IN ASD
Individual serum samples from ASD (30) and healthy controls (30) were analyzed using stemloop qRT-PCR pooling assay. Pooled samples were created by physically adding an equivalent amount of serum volume from each individual ASD sample and healthy controls and fi nally adjusted to 300 μl VALIDATED MICRORNA TARGET GENE ANALYSIS To study the potential modulation in gene expression that may be associated with specifi c serum miRNAs changes, miRNA validated target studies were carried out using the publicly available database, miRWalk -Database. 17 The validated targets module hosted experimentally verifi ed miRNA interaction information associated with target genes were used.
RESULTS
POOLED EXPRESSION ANALYSIS OF SERUM MICRORNAS IN CHILDREN WITH ASD
In the preliminary expression experiments 42 miRNA molecules were selected as candidate biomarkers for initial analysis. We found that 29 miRNAs were downregulated (miR-589-3p, -6849-3p, -3135a, -15a-5p, -328-3p, -183-5p, -3674, -96-5p, -3687, -6799-3p, -587-3p, -504-5p, -576-5p, -486-3p, -3909, -let-7i-3p, -29c-5p, -301a-3p, -3064-5p, -145-5p, -424-5p, -193b-3p, -487b-3p, -197-5p, -500a-5p, -664b-3p, -20b-3p, -671-3p and -199a-5p) and 11 were upregulated (miR-4489, -8052, -106b-5p, -142-3p, -3620-3p, -365a-3p, -664a-3p, -374b-5p, -18b-3p, -619-5p, and 210-5p), while two of the selected 42 miRNAs did not show any expression changes in children with ASD compared to general population controls (Fig. 1) . Bars represent the fold change in subjects with ASD as compared to controls. We further confi rmed the expression of the eight most dysregulated serum miRNAs using qRT-PCR pooled analysis. The results showed that the serum relative levels of only three miRNAs (miR-365a- 3p, miR-619-5p and miR-664a-3p) in ASD patients were markedly higher than these in control patients, and the serum relative levels of other fi ve miR3135a, miR-328-3p, miR-197-5p, miR-500a-5p, and miR-424-5p in ASD patients were lower than that in control patients (Fig. 2) . Fold changes in the expression of microRNAs in serum from patients with ASD compared with healthy control individuals are summarized ( Table 2) . PCR amplifi cation of the specifi c products corresponding to all miRNAs amplicons was confi rmed by monitoring the dissociation curve (Melting curve analysis) (Fig. 3) .
TARGET GENE ANALYSIS OF DYSREGULATED MIRNAS IN ASD
A list of validated protein coding gene targets for the dysregulated miRNAs (miR-424-5p, miR-197-5p, miR-328-3p, miR-500a-5p, miR-619-5p, miR-3135a, miR-664a-3p, and miR-365a-3p) was generated by data extraction from miRWalk database ( Table 3) . Specifi c downstream targets of the dysregulated miRNAs miR-328-3p and miR-619-5p include some genes related to mediation of the infl ux of calcium ions into the cell upon membrane polarization (calcium channel, voltage-dependent, L type, alpha 1C subunit (CACNA1C) and calcium channel, voltagedependent, beta 1 subunit (CACNB1) as well as other genes involved in epigenetic processes like dicer 1, ribonuclease type III (DICER). We also identify other miR-424-5p validated target gene like RNASEN (drosha, ribonuclease type III).
DISCUSSION
The benefi ts of miRNAs as biomarkers for various diseases has been intensively investigated and some promising potential candidates have been explored. The advantages of circulating miRNAs in contrast to other nucleic acid molecules are that they show an unexpected stability in different body fl uids. MiRNAs can stay stable not only in the RNaserich blood environment, but also in extreme conditions, including boiling temperatures, high or low pH, long storage, and freeze-thaw cycles. 18 Most Figure 2 . Expression of the eight dysregulated miRNAs using qRT-PCR in pooled analysis. The circulating serum miRNAs signatures identifi ed by stem-loop qRT-PCR analysis of several miRNAs differentially expressed in case and control groups. Expression levels of the analyzed miRNAs were normalized to spiked-in Cel-miR-39 control and expressed in relation to controls. the sensitivity and specifi city of the diagnosis. In addition, because biofl uids contain very low amount of circulating miRNAs, extracting miRNA from serum or plasma is technically challenging. Another major challenge for the analysis is the choice of suitable endogenous controls. Data normalization is another crucial question. Therefore, it is of vital importance to develop standardization methods for quantifying the circulating miRNA. Regardless of these obstacles, the application value of circulating miRNAs in different diseases is gradually being revealed.
In this study, we have performed miRNA specifi c stem loop qRT-PCR assay in order to identify microRNAs involved in ASD. Here, we intend to identify serum microRNAs that are specifi c and can be used to discriminate ASD patients from healthy controls. In a preliminary step of our study (Fig. 1) we identifi ed 11 microRNAs that are upregulated and 29 that are downregulated in ASD patients compared with group of healthy controls. Among the differentially expressed miRNAs, 8 displayed highly dysregulated expression profi le. Our results confi rm the fi ndings of M.M. Vasu et al., (2015) showing the same expression profi le of miRNAs (miR-106b-5p and miR-328). 21 Additionally, we detected some dysregulated miRNAs that have not been previously reported (miR-365a-3p, miR-3135a, miR-619-5p, miR-664-3p, miR-197-5p, miR-500a-5, miR-424-5p). Some of the above mentioned miRNAs were analyzed in previous reports ( Table 4) . 19 So far, three studies have identifi ed expression of miRNAs in a post-mortem brain -cerebellar cortex, prefrontal cortex and temporal cortex of ASD patients. 3, 20, 21 Bradley P. Ander et al. observed alterations in miRNA expression and their functional relation to the nervous system and canonical signaling pathways implicated in ASD. It was interesting that hsa-miR 664a-3p that we identifi ed as differentially expressed in our study has been described in Bradley P. Ander et al. study of post-mortem temporal cortex of ASD subjects and has the same alteration in the expression pattern. 21 This makes miRNAs such as miR 664a-3p interesting potential -424-5p  ATF6, BMPER, INPPL1, KIF23, ENDOGL1, MBD4, USF2, NFKB1, CCND3,  BCR, EIF2C1, FGF2, CDC25A, MAP2K1, E2F1, YY1, NOS2A, CCNE1, SETD2,  PAK3, CAMTA1, NIT1, CEBPB, ESR1, RUNX1, PTGS2, CREB1, HIF1A, ITGB1,  MED1, KCNH8, NUDT6, DDX20, SMAD3, OPRS1, PDXP, AKT1, CUL2,  POU2F2, CXCL12, MAPK9, CREB1, FGFR1, EIF2C2, MYB, CHD4, IL6, JUN,  LATS2, BCL6, RUNX2, MAP2K1, ATF2, KDR, EGFR, RARA, AP2M1, EPHB2,  CCND1, MYB, WEE1, CBFB, RASA1, E2F3, VEGFA, LGALS3, RXRA, DDX5,  ITGAL, PLAG1, SIAH1, CDC14A, CD44, TAF10, HOXA4, MUC1, GTF2IRD1 biomarker for ASD. Many differentially expressed miRNAs, such as the eight microRNAs analyzed in this study using qRT-PCR, are involved in various biological processes including proliferation, migration, differentiation and apoptosis.
The study of the differential expression of miRNA molecules is very important since alterations in the expression levels of miRNA molecules as a class (regulatory molecules) are expected to infl uence the transcription/translation of a number amino terminus and an RNA motif in the carboxy terminus. The encoded protein functions as a ribonuclease and is required by the RNA interference and small temporal RNA (stRNA) pathways to produce the active small RNA component that represses gene expression. RNASEN (drosha, ribonuclease type III) -the RNase III Drosha is the core nuclease that executes the initiation step of microRNA (miRNA) processing in the nucleus.
Additional benefi t of this study is that the samples came from ASD patients aged between 3 and 11 years in comparison with previous report from Vasu et al. where serum miRNAs profi le were analyzed in older individuals ranging from 6 to 16 years of age.
In conclusion, our fi ndings supports the fact that levels of circulating miRNAs can be dysregulated under certain disease conditions. We found that miR-365a-3p, miR-619-5p, miR-664a-3p are the most upregulated and miR-3135a, miR-328-3p, miR-197-5p, miR-424-5p, miR-500a-5p are downregulated in the serum of patients with ASD. We suggest that this could refl ect a metabolic imbalance of this miRNA in vivo and these miRNAs could be used as biomarkers of ASD. A greater sample size of patients with ASD is still needed in order to support these conclusions.
